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Abstract
We report here the first identification of the worldwide spread of
Klebsiella pneumoniae carbapenemase-2-producing and carbape-
nem-resistant K. pneumoniae clone ST258 in Turkey, a country
where the distantly-related carbapenemase OXA-48 is known to
be endemic. Worryingly, this isolate was also resistant to colistin,
now considered to be the last-resort antibiotic for carbape-
nem-resistant isolates.
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Carbapenem-resistant enterobacterial isolates, currently
spreading worldwide, are of major public health concern in
both developed and developing countries [1]. Among the most
commonly identified carbapenemases identified in Enterobac-
teriaceae, are the Klebsiella pneumoniae carbapenemases (KPC)
[1].
We report here on an 80-year-old female patient trans-
ferred from a Romanian hospital and admitted in November
2012 to the Intensive Care Unit of a hospital located close to
Istanbul, Turkey. Upon admission she presented severe
nosocomial pneumonia. Sputum culture grew Acinetobacter
baumannii, and a rectal swab taken for screening purposes
grew an extended-spectrum b-lactamase-producing K. pneu-
moniae. The patient was treated with meropenem for 14 days
and a carbapenem-resistant K. pneumoniae (isolate A) was
isolated from an endotracheal aspirate culture 21 days after
her admission. Colistin was added to the meropenem and,
after 10 days, endotracheal aspirate cultures remained nega-
tive and the antibiotic regimen was discontinued. Four days
after the antibiotherapy was stopped, a carbapenem-resistant
and colistin-resistant K. pneumoniae (isolate B) was recovered
from an endotracheal aspirate culture. The patient developed
sepsis, multiple organ failure and died at day 56 of her
hospitalization.
Susceptibility testing performed and interpreted according
to the updated CLSI guidelines [2] showed that K. pneumoniae
isolates A and B were susceptible only to cefepime, but were
resistant to all other b-lactams including carbapenems. The
MICs of carbapenems for both isolates determined by E-test
(bioMerieux, La Balme-les-Grottes, France) were 8, 8, and
32 mg/L for imipenem, meropenem and ertapenem, respec-
tively. In addition, they were resistant to all aminoglycosides,
to fluoroquinolones, nitrofurantoin, chloramphenicol and
trimethoprim–sulphamethoxazole. The MICs of tigecycline
and colistin of isolate A measured by E-test were 0.25 and
0.094 mg/L, respectively, whereas those of isolate B were 0.25
and 4 mg/L, respectively.
Detection of any carbapenemase activity using the Carba
NP test [3] gave a positive result. Therefore, PCR assays were
performed to identify the type of carbapenemase produced,
with a series of primers designed for the detection of blaKPC,
blaIMP, blaVIM, blaNDM and blaOXA-48 carbapenemase genes [4],
and PCR and sequencing identified the blaKPC-2 gene.
Pulsed-field gel electrophoresis analysis indicated that both
isolates were clonally related, exhibiting identical restriction
patterns (data not shown).
Mating-out assays produced an Escherichia coli transconju-
gant expressing KPC-2, exhibiting a reduced susceptibility to
carbapenems (MICs of 0.5, 2 and 0.38 mg/L for ertapenem,
imipenem and meropenem, respectively), harbouring a single
120-kb plasmid typed as an IncFII by PCR-based replicon typing
[5]. Further PCR mapping showed that blaKPC-2 was part of
transposon Tn4401b [1].
Multilocus sequence typing performed as described else-
where (http://pubmlst.org) identified isolates A and B as
belonging to sequence type (ST) 258, being the most
commonly identified ST among KPC-producing K. pneumoniae
worldwide.
The successful spread of the ST258 KPC-2-positive K. pneu-
moniae clone is well recognized. However, it had so far never
been identified in Turkey, a country with a specific epidemi-
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ology, where OXA-48 carbapenemase has been extensively
identified for a decade [1], but only a single report of imported
NDM-1-producing K. pneumoniae is known [6]. Worryingly,
we report here the in vivo selection of a colistin-resistant
KPC-producing K. pneumoniae isolate under combined ther-
apy. That selection occurred in a critically ill patient who later
died of that infection. This shows that the current spread of
carbapenem non-susceptible isolates is extremely worrisome,
considering that colistin will not solve all therapeutic problems.
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